Inovio Pharmaceuticals Soars 12.28% on Q2 Earnings, Clinical Progress

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) rose 12.28% in pre-market trading on August 15, 2025, driven by positive developments in its second-quarter financial results and clinical progress.

Inovio Pharmaceuticals reported a net loss of $23.5 million for the second quarter of 2025, a 27% reduction from the same period last year. The company's operating expenses decreased by 30.6%, reflecting cost management efforts. Despite no reported revenue, the company's financial runway was extended through Q2 2026 due to a recent capital raise.

The company made significant progress with its lead candidate, INO-3107, for recurrent respiratory papillomatosis (RRP). Inovio completed device verification testing for its CELLECTRA 5PSP device and remains on track to submit a Biologics License Application (BLA) to the FDA in the second half of 2025. Clinical data showed durable efficacy, with 86% of patients experiencing a reduction in required surgeries.

Inovio also advanced its DNA-encoded monoclonal antibodies (DMAb) platform, showing promising results in a COVID-19 study with durable antibody production. The company continues to focus on regulatory approval for INO-3107 and strategic partnerships to support its commercialization efforts.